Minerva Neurosciences, Inc. announced that Fouzia Laghrissi-Thode, M.D. has been appointed to board of directors. Dr. Laghrissi-Thode brings extensive experience in global pharmaceutical development to and has held positions of leadership at AstraZeneca, Roche, Novartis and Sandoz in a broad range of therapeutic areas. She is currently vice president of the cardiovascular and metabolism therapy area at AstraZeneca.

William Boni has been named vice president of investor relations and corporate communications. Mr. Boni joins Minerva from ArQule, Inc. He has experience in the biopharmaceutical industry, including corporate positions with Interneuron /Indevus Pharmaceuticals and Curis, Inc. His agency experience includes Hill & Knowlton and Feinstein Partners.